Evaluating the reactogenicity of COVID-19 vaccines from network-meta analyses

References

• World Health Organization. WHO Coronavirus (COVID-19) Dashboard [Internet]. [cited 2022 Nov 8]. Available from: https://covid19.who.int/
   Google Scholar
• World Health Organization. COVID-19 vaccine tracker and landscape [Internet]. [cited 2022 Nov 8]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
   Google Scholar
• European Medicines Agency. COVID-19 vaccines: authorised [Internet]. [cited 2022 Aug 9]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised#authorised-covid-19-vaccines-section
   Google Scholar
• Our World in Data. Coronavirus (COVID-19) Vaccinations [Internet]. [cited 2022 Nov 8]. Available from: https://ourworldindata.org/covid-vaccinations#citation
   Google Scholar
• Levin EG, Lustig Y, Cohen C, et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med. 2021;385(24):1–11. DOI:10.1056/NEJMoa2114583
   PubMed Web of Science ®Google Scholar
• Menni C, May A, Polidori L, et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Lancet Infect Dis. 2022 Jul 1;22(7):1002–1010. DOI:10.1016/S1473-3099(22)00146-3
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. CDC Strengthens Recommendations and Expands Eligibility for COVID-19 Booster Shots [Internet]. [cited 2022 Aug 9]. Available from: https://www.cdc.gov/media/releases/2022/s0519-covid-booster-acip.html#:~:text=CDC%20Strengthens%20Recommendations%20and%20Expands%20Eligibility%20for%20COVID%2D19%20Booster%20Shots,-Media%20Statement&text=Following%20today’s%20meeting%20of%20the,years%20of%20age%20and%20older.
   Google Scholar
• Dodd RH, Pickles K, Nickel B, et al. Concerns and motivations about COVID-19 vaccination. Lancet Infect Dis. 2021;21(2): 161–163. DOI:10.1016/S1473-3099(20)30926-9
   PubMed Web of Science ®Google Scholar
• Flash Eurobarometer 505 – Ipsos European Public Affairs. Attitudes on vaccination against COVID-19 - February 2022. 2022.
   Google Scholar
• Reno C, Maietti E, Fantini MP, et al. Enhancing COVID-19 vaccines acceptance: results from a survey on vaccine hesitancy in northern Italy. Vaccines (Basel). 2021 Apr 1;9(4). doi:10.3390/vaccines9040378
   Web of Science ®Google Scholar
• Biswas N, Mustapha T, Khubchandani J, et al. The Nature and Extent of COVID-19 Vaccination Hesitancy in Healthcare Workers. Vol. 46. Journal of Community Health. Springer; 2021. p. 1244–1251. DOI:10.1007/s10900-021-00984-3
   Google Scholar
• Preliminary public health considerations for COVID-19 vaccination strategies in the second half of 2022. 2022.
   Google Scholar
• Valneva. Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001 [Internet]. [cited 2022 Aug 9]. Available from: https://valneva.com/press-release/valneva-receives-marketing-authorization-in-europe-for-inactivated-whole-virus-covid-19-vaccine-vla2001/#:~:text=Saint%20Herblain%20France%2C%20June,as%20primary%20vaccination%20in%20people
   Google Scholar
• Li T, Puhan MA, Vedula SS, et al. Network meta-analysis-highly attractive but more methodological research is needed. BMC Med. 2011;9(1). DOI:10.1186/1741-7015-9-79
   Google Scholar
• Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015 Jun 2;162(11):777–784. DOI:10.7326/M14-2385
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviewsVol. 372, The BMJ. BMJ Publishing Group; 2021. DOI:10.1136/bmj.n71
   Google Scholar
• Dias S, Ades AE, Welton NJ, Adverse Events and Other Sparse Outcome Data. Network Meta‐Analysis for Decision Making. John Wiley & Sons Ltd; 2018. DOI:10.1002/9781118951651.ch6
   Google Scholar
• Beatty AL, Peyser ND, Butcher XE, et al. Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination. JAMA Netw Open. 2021;4(12):1–13. DOI:10.1001/jamanetworkopen.2021.40364
   Web of Science ®Google Scholar
• Turner RM, Jackson D, Wei Y, et al. Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis. Stat Med. 2015;34(6):984–998.
   PubMed Web of Science ®Google Scholar
• Dias S, Sutton AJ, Ades AE , et al. NICE DSU Technical Support Document 2: a Generalized Linear Modeling Framework for Pairwise and Network Meta-analysis of Randomised Controlled Trials. London: National Institute for Health and Care Excellence (NICE). 2014. Accessed 9 August 2022. https://www.ncbi.nlm.nih.gov/books/NBK310366/
   Google Scholar
• Salanti G, Nikolakopoulou A, Efthimiou O, et al. Introducing the Treatment Hierarchy Question in Network Meta-Analysis. Am J Epidemiol. 2022 May 1;191(5):930–938.
   PubMed Web of Science ®Google Scholar
• Kelland K, Jones G, Italy GF, Britain suggest age limits for AstraZeneca vaccine but still recommend it [Internet]. Reuters. [cited 2022 Apr 21]. Available from: https://www.reuters.com/article/health-coronavirus-astrazeneca-idUSKBN2BU1R0
   Google Scholar
• Wu Q, Dudley MZ, Chen X, et al. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Med. 2021 Dec 1;19(1). doi:10.1186/s12916-021-02059-5
   Web of Science ®Google Scholar
• Pormohammad A, Zarei M, Ghorbani S, et al. Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trialsVol. 9, Vaccines. MDPI AG; 2021. DOI:10.3390/vaccines9050467
   Google Scholar
• Zhang R Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines _ Enhanced Reader.
   Google Scholar
• Howick J, Webster R, Kirby N, et al. Rapid overview of systematic reviews of nocebo effects reported by patients taking placebos in clinical trials. Vol. 19. Trials. BioMed Central Ltd.; 2018. DOI:10.1186/s13063-018-3042-4
   Google Scholar
• Haas JW, Bender FL, Ballou S, et al. Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials: a Systematic Review and Meta-analysis. JAMA Network Open. American Medical Association; 2022. DOI:10.1001/jamanetworkopen.2021.43955
   Google Scholar
• Mbuagbaw L, Rochwerg B, Jaeschke R, et al. Approaches to interpreting and choosing the best treatments in network meta-analysesVol. 6, Systematic Reviews. BioMed Central Ltd.; 2017. DOI:10.1186/s13643-017-0473-z
   Google Scholar
• Woods BS, Hawkins N, Scott DA. Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial. BMC Med Res Methodol. 2010;10(1):10.
   PubMedGoogle Scholar